Inducing Potent and Durable T Cell Responses to Fight Disease
Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.
Bill Enright, CEO of Vaccitech, discusses the company’s platform technologies, how they work, and how they enable the development of more effective immunotherapies.